ArticleCancer gene therapy2013
Decreasing P-selectin and ICAM-1 via activating Akt: a possible mechanism by which PARG inhibits adhesion of mouse colorectal carcinoma CT26 cells to platelets.
Article in Cancer gene therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Poly (ADP-ribose) glycohydrolase (PARG), which was discovered during studies on DNA damage study and in inflammation research, is an attractive target protein in current cancer research. The enzymatic hydrolysis of poly (ADP-ribose) (PAR) has not been clarified in the regulation of cancer. The purpose of this study was to understand the relationship between PARG and the adhesion of colorectal carcinoma CT26 cells to platelets. PARG was silenced by short hairpin RNA (shRNA) transfection in CT26 cells. A fluorescence method was used to identify adhesion of CT26 cells to platelets and the expression of poly (ADP-ribose) polymerase (PARP)-1, p-Akt, nuclear factor kappa-B (NF-κB), P-selectin and intercellular adhesion molecule-1 (ICAM-1) was analyzed by western blot in various treated groups and control groups. The results were as follows: (a) PARG silencing led to inhibition of adhesion of CT26 cells to platelets, whereas an inhibitor of p-Akt boosted adhesion of PARG-short hairpin RNA interference (shRNAi) CT26 cells to platelets; (b) a PARP-1 inhibitor depressed the expression of P-selectin and ICAM-1 in CT26 cells; (c) PARG silencing increased phosphorylation of Akt and decreased expression of PARP-1, NF-κB, ICAM-1 and P-selectin in CT26 cells; and (d) a p-Akt inhibitor intensified expression of NF-κB, ICAM-1 and P-selectin in PARG-shRNAi CT26 cells accordingly. These results showed the effectiveness of knockout of PARG in inhibiting adhesion of CT26 cells to platelets and its connection with the phosphatidylinositol 3 kinase/Akt pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.